The X-linked adrenoleukodystrophy (ALD) is a severe neurodegenerative disorder due to mutations in the ABCD1 gene. Objective: To report a case of a 19-year-old man with adrenal insufficiency due to adrenoleukodystrophy. Method: Case report and literature review. Result: A previously healthy 19-year-old male patient was admitted to the emergency room with nausea and vomiting for 5 days, who progressed to abdominal pain, severe asthenia, and fever (38.5°C). He referred progressive darkening of the skin, oral mucosa, tongue and nail bed of the hands and feet, observed in the last 6 years. Emergency laboratory evaluation showed severe hyponatremia and hyperkalemia, which, together with decreased plasma cortisol, directed the investigation to causes of adrenal insufficiency. High ACTH (Adrenocorticotropic hormone) and very long chain fatty acid levels closed the diagnosis. Discussion: ALD is characterized by progressive demyelination in the central and peripheral nervous system and adrenal insufficiency consequence to the accumulation of very long chain fatty acids (VLCFA) in the adrenal. The overall incidence of ALD is 1:17,000. Adrenal insufficiency may be the first symptom of ALD in boys and adults. The diagnosis is based on the measurement of VLCFA plasma levels. Allogeneic bone marrow transplantation is the only treatment that provides a permanent cure when the procedure is performed at an early stage of brain demyelination, i.e. when patients are asymptomatic, although brain magnetic resonance imaging (MRI) is abnormal. Treatment of Addison’s disease is obligatory, but does not change the course of neurological symptoms.
References
[1]
Bezman, L., et al. (2001) Adrenoleukodystrophy: Incidence, New Mutation Rate, and Results of Extended Family Screening. Annals of Neurology, 49, 512-517.
https://doi.org/10.1002/ana.101
[2]
Kemp, S., et al. (2016) Adrenoleukodystrophy—Neuroendocrine Pathogenesis and Redefinition of Natural History. Nature Reviews Endocrinology, 12, 606-615.
https://doi.org/10.1038/nrendo.2016.90
[3]
Pereira Fdos, S., et al. (2012) Mutations, Clinical Findings and Survival Estimates in South American Patients with X-Linked Adrenoleukodystrophy. PLoS ONE, 7, e34195. https://doi.org/10.1371/journal.pone.0034195
[4]
Engelen, M.S. and Kemp, B.T. (2014) X-Linked Adrenoleukodystrophy: Pathogenesis and Treatment. Current Neurology and Neuroscience Reports, 14, 486.
https://doi.org/10.1007/s11910-014-0486-0
[5]
Maciel, K.A.C. and Oliveira, M.S. (2012) Diagnóstico e tratamento da adrenoleucodistrofia ligada ao X. XII Safety, Health and Environment World Congress, Sao Paulo, 22-25 July 2012, 10.
[6]
Eichler, F., et al. (2017) Hematopoietic Stem Cell Gene Therapy for Cerebral Adrenoleukodystrophy. The New England Journal of Medicine, 377, 1630-1638.
[7]
Kaltsas, G., Kanakis, G. and Moser, H. (2015) Adrenal Insufficiency Due to X-Linked Adrenoleukodystrophy. MDText.com, South Dartmouth.
[8]
Moser, H., Dubey, P. and Fatemi, A. (2004) Progress in X-Linked Adrenoleukodystrophy. Current Opinion in Neurology, 17, 263-269.
https://doi.org/10.1097/00019052-200406000-00005
[9]
Santos, A.C. (2014) Adrenoleucodistrofia ligada ao X: Diagnóstico e quantificacao da progressao. Radiologia Brasileira, 47, 7-8.
https://doi.org/10.1590/0100-3984.2014.47.6e2
[10]
Engelen, M.S. (2017) Optimizing Treatment for Cerebral Adrenoleukodystrophy in the Era of Gene Therapy. The New England Journal of Medicine, 377, 1682-1684.
https://doi.org/10.1056/NEJMe1709253
[11]
Jorge, P., et al. (1994) X-Linked Adrenoleukodystrophy in Patients with Idiopathic Addison Disease. European Journal of Pediatrics, 153, 594-597.
https://doi.org/10.1007/BF02190668
[12]
Spurek, M., Taylor-Gjevre, R., Van Uum, S. and Khandwala, H.M. (2004) Adrenomyeloneuropathy as a Cause of Primary Adrenal Insufficiency and Spastic Paraparesis. Canadian Medical Association Journal, 171, 1073-1077.
https://doi.org/10.1503/cmaj.1032006
[13]
Aubourg, P. (2007) X-Linked Adrenoleukodystrophy. Annales d’Endocrinologie, 68, 403-411.
[14]
Melhem, E.R., et al. (2000) X-Linked Adrenoleukodystrophy: The Role of Contrast-Enhanced MR Imaging in Predicting Disease Progression. American Journal of Neuroradiology, 21, 839-844.
[15]
Moser, H.W., et al. (2000) X-Linked Adrenoleukodystrophy: Overview and Prognosis as a Function of Age and Brain Magnetic Resonance Imaging Abnormality. A Study Involving 372 Patients. Neuropediatrics, 31, 227-239.
https://doi.org/10.1055/s-2000-9236
[16]
Salsano, E., et al. (2014) Brain Fluorodeoxyglucose PET in Adrenoleukodystrophy. Neurology, 83, 981-989. https://doi.org/10.1212/WNL.0000000000000770
[17]
Raymond, G.V., Moser, A.B. and Fatemi, A. (2018) X-Linked Adrenoleukodystrophy. Gene Reviews.
[18]
Higgins, C.F. (1992) ABC Transporters: From Microorganisms to Man. Annual Review of Cell Biology, 8, 67-113.
https://doi.org/10.1146/annurev.cb.08.110192.000435
[19]
Burtman, E. and Regelmann, M.O. (2016) Endocrine Dysfunction in X-Linked Adrenoleukodystrophy. Endocrinology and Metabolism Clinics of North America, 45, 295-309. https://doi.org/10.1016/j.ecl.2016.01.003
[20]
Whitcomb, R.W., Linehan, W.M. and Knazek, R.A. (1988) Effects of Long-Chain, Saturated Fatty Acids on Membrane Microviscosity and Adrenocorticotropin Responsiveness of Human Adrenocortical Cells in Vitro. Journal of Clinical Investigation, 81, 185-188. https://doi.org/10.1172/JCI113292
[21]
Knazek, R.A., Rizzo, W.B., Schulman, J.D. and Dave, J.R. (1983) Membrane Microviscosity Is Increased in the Erythrocytes of Patients with Adrenoleukodystrophy and Adrenomyeloneuropathy. Journal of Clinical Investigation, 72, 245-248.
https://doi.org/10.1172/JCI110963
[22]
Powers, J.M. and Schaumburg, H.H. (1973) The Adrenal Cortex in Adrenoleukodystrophy. Archives of Pathology & Laboratory Medicine, 96, 305-310.
[23]
Hannah-Shmouni, F., et al. (2016) Cortisol in the Evaluation of Adrenal Insufficiency. JAMA, 316, 535-536. https://doi.org/10.1001/jama.2016.8360
[24]
Laureti, E., et al. (1996) X-Linked Adrenoleukodystrophy Is a Frequent Cause of Idiopathic Addison’s Disease in Young Adult Male Patients. Journal of Clinical Endocrinology and Metabolism, 81, 470-474. https://doi.org/10.1210/jc.81.2.470
[25]
Shulman, D.I., et al. (2007) Adrenal Insufficiency: Still a Cause of Morbidity and Death in Childhood. Pediat-rics, 119, e484-e494.
https://doi.org/10.1542/peds.2006-1612
[26]
Salvatori, R. (2005) Adrenal Insufficiency. JAMA, 294, 2481-2488.
https://doi.org/10.1001/jama.294.19.2481
[27]
Oelkers, W. (1996) Adrenal Insufficiency. The New England Journal of Medicine, 335, 1206-1212. https://doi.org/10.1056/NEJM199610173351607
[28]
Fleseriu, M., Hashim, I.A., Karavitaki, N., Melmed, S., Murad, M.H., Salvatori, R. and Samuels, M.H. (2016) Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 101, 3888-3921. https://doi.org/10.1210/jc.2016-2118
[29]
Bornstein, S.R., et al. (2016) Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 101, 364-389. https://doi.org/10.1210/jc.2015-1710
[30]
Wanders, R.J.A., Mooyer, P.W., Dekker, C. and Vreken, P. (1998) X-Linked Adrenoleukodystrophy: Improved Prenatal Diagnosis Using Both Biochemical and Immunological Methods. Journal Inherited Metabolic Disease, 21, 285-287.
https://doi.org/10.1023/A:1005336726127
[31]
Ono, S.E., et al. (2014) X-Linked Adrenoleukodystrophy: Correlation between Loes Score and Diffusion Tensor Imaging Parameters. Radiologia Brasileira, 47, 342-349.
https://doi.org/10.1590/0100-3984.2013.1886
[32]
Loes, D.J., et al. (2003) Analysis of MRI Patterns Aids Prediction of Progression in X-Linked Adrenoleukodystrophy. Neurology, 61, 369-374.
https://doi.org/10.1212/01.WNL.0000079050.91337.83
[33]
Silva, R.C., et al. (2004) Insuficiência Adrenal Primária no Adulto: 150 Anos Depois de Addison. Arquivos Brasileiros de Endocrinologia & Metabologia, 48, 724-738.
https://doi.org/10.1590/S0004-27302004000500019
[34]
Betterle, C. and Morlin, L. (2011) Autoimmune Addison’s Disease. Endocrine Development, 20, 161-172. https://doi.org/10.1159/000321239
[35]
Ferrer, I., Aubourg, P. and Pujol, A. (2010) General Aspects and Neuropathology of X-Linked Adrenoleukodystrophy. Brain Pathology, 20, 817-830.
https://doi.org/10.1111/j.1750-3639.2010.00390.x
[36]
Vogel, B.H., et al. (2015) Newborn Screening for X-Linked Adrenoleukodystrophy in New York State: Diagnostic Protocol, Surveillance Protocol and Treatment Guidelines. Molecular Genetics and Metabolism, 114, 599-603.
https://doi.org/10.1016/j.ymgme.2015.02.002
[37]
Jorge, P.M.V. (2000) Adrenoleucodistrofia ligada ao cromossoma X: Estudos bioquímicos e moleculares. Porto, Tese (Doutor em Ciências Biomédicas, especialidade Genética Humana) Universidade do Porto, 153 p.
[38]
Cartier, N., et al. (2009) Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy. Science, 326, 818-823.
https://doi.org/10.1126/science.1171242
[39]
Vargas, C.R., et al. (2000) X-Linked Adrenoleukodystrophy: Clinical and Laboratory Findings in 15 Brazilian Patients. Genetics and Molecular Biology, 23, 261-264.
https://doi.org/10.1590/S1415-47572000000200002
[40]
Ten, S., et al. (2001) Addison’s Disease. The Journal of Clinical Endocrinology & Metabolism, 86, 2909-2922. https://doi.org/10.1210/jc.86.7.2909
